Full-Time

Key Account Manager

Posted on 9/7/2025

Deadline 10/15/25
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

No salary listed

Mumbai, Maharashtra, India

In Person

Category
Sales & Account Management (1)
Required Skills
Inventory Management
Data Analysis
Requirements
  • Degree in Sciences / B Pharm / Equivalent
  • 5 or more year’s relevant experience (Minimum 3 years’ experience in Oncology Sales)
  • Proven experience in articulating data-driven findings to various audience levels and translating these findings into actionable recommendations.
Responsibilities
  • Proficient with the therapy and product related features/benefits including scientific information thereto, so as to effectively communicate with the medical doctors and handle product related customer queries.
  • Actively participate in identifying key and potential medical practitioners and specialists in the respective therapeutic segment in the assigned territory, and prioritize for the purpose of systematic customer coverage so as to generate maximum prescription sales for the company’s range of products as per business plan.
  • Schedule and plan the frequency of calls and personally visit the targeted doctors as per agreed coverage list. Call on the Chemists, wholesalers as the case may be to track in-market sales of the products, booking of orders to ensure timely and adequate availability of products to meet market demand.
  • Utilize customer focused selling techniques (CSSP), continually assessing the knowledge of the customer and strategize to maintain high customer confidence and customer knowledge of company products.
  • Maintain current, approved protocol (CSSP) and promotional materials to be included in sales presentation/ detailing.
  • Contact customers on regular basis and deliver informative sales presentations based on customers need.
  • Constantly explore opportunities to develop new business within assigned therapy area.
  • Achieve and exceed the sales targets on a consistent basis through effective implementation of the sales promotion strategies and follow-up initiatives.
  • Specialist in the product knowledge, therapy knowledge and detailing skills so as to enhance productivity levels as expected by the Company.
  • Carry out Product Visibility and such ancillary or incidental activities related to the Products of the Company or Products of any other Company as may be decided from time to time, in accordance with any arrangement or agreement entered into by the Company with such other Company.
  • Explore opportunities to develop new businesses within assigned therapy area.
  • Tactically plans to generate tertiary demand generation.
  • Plans and executes field working as per approved tour programmes so as to cover all stakeholders as per decided frequency.
  • Takes follow-up initiatives on feedback and customer service requirements.
  • Handles special product campaigns, new product launch campaigns as per Company’s plans.
  • Covers the Nursing homes, clinics and hospitals as per agreed coverage requirements.
  • Collects data on annual budget for medicines, mode of purchase, rate contract/tendering etc. as may be required and takes initiatives to tap these business growth avenues.
  • Assists in the collection of receivables, as per company policy.
  • To nurture strategic relationships with top accounts, so a KAM must possess an in-depth knowledge of the company and its customers.
  • KAMs need to have a strategic perspective that goes beyond short-term gains. They must be able to juggle many moving parts and orchestrate deals and long-term plans that align with a mutually beneficial strategy.
  • Actively participate in Cycle meetings, periodic Sales & Marketing meeting and conventions.
  • Conducts group meetings, medical education camps, speaker programmes as may be necessary from time to time for assigned therapy area.
  • Guides and helps other team members within therapy area to design and execute scientific activities as per experience.
  • Actively participate in training, orienting and handholding the new comers.
  • To be a Mentor to the Trainees, probationers and freshly inducted sales professionals in the assigned therapy area.
  • Expert in the therapy area and constantly providing guidance and coaching to TMs and STMs as per need.
  • To sanction leave of the sales professionals, as per company procedure.
  • Liaising with the Stockists and distributors in connection with customer service requirements. Provides guidance and coaching to TMs as per need.
  • To approve claims upto prescribed limits of authorized stockists, distributors, retailers in respect of breakages, date expiry, spoilage etc after due verification. In case of larger claims, provide accurate and vital inputs to the Management to take appropriate action.
  • Demonstrate above average knowledge of all company marketed products, disease, therapy area, competitor products, promotional strategies and objectives. Develops a clear understanding of the Company’s SOPS and protocols pertaining to his area of work.
  • Imbibes the guidelines pertaining to Adverse Event Reporting and takes prompt action in compliance with the requirements.
  • Maintain quality customer list, current profile of assigned key accounts, key influencers & clinical thought leaders.
  • Execute Marketing Strategies in consonance with Marketing guidelines.
  • Collect Market intelligence, conduct market surveys, participate in special projects etc.
  • Actively seek and display knowledge of key customers in territory and therapy area.
  • Lead the scientific engagement of key stakeholders within therapy area so as to establish leading corporate image.
  • Develop and maintain strong relationships with customers and build up a healthy rapport with them.
  • Work collectively with other team colleagues in arranging speakers, displays, special programs and CMEs to meet the educational needs of customers.
  • Ensure adequate inventory level with trade partner and take prompt actions to prevent date expiry of products.
  • Ensure timely submission of daily call report, sales documents, feedback reports, expense reports and other administrative duties are completed in an accurate and timely manner.
  • Adhere and demonstrate Leader behaviors.
  • In the discharge of your responsibilities, you will be required to undertake such other jobs as may be assigned to you by the Management from time to time.
Desired Qualifications
  • Account Management
  • Adaptability
  • Bidding Process
  • Commercial Account Management
  • Contract Management
  • Customer Experience Management
  • Data-Driven Marketing
  • Demand Generation
  • Healthcare Education
  • Hospital Experience
  • Management Process
  • Marketing Capabilities
  • Oncology Sales
  • Operational Delivery
  • Product Knowledge
  • Project Planning
  • Relationship Management
  • Sales Operations
  • Sales Process Management
  • Strategic Planning

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approves IDVYNSO HIV therapy launching post-May 11, 2026.
  • Keytruda Qlex adds $128 million Q1 sales with administration advantages.
  • Peenya facility expands for filtration, targeting $14.06B market by 2035.

What critics are saying

  • Keytruda patent expires 2028, biosimilars slash $8B quarterly sales 70%.
  • Gardasil trial starts July 27, 2026, erodes trust amid RFK Jr. involvement.
  • Gardasil sales drop 19% Q1 2026 from Chinese competition permanently.

What makes Merck unique

  • Keytruda generates $8 billion in Q1 2026 sales, up 12% year-over-year.
  • Winrevair surges 88% to $525 million in Q1 2026 across US, Japan, Europe.
  • Cidara Therapeutics $9.2 billion acquisition bolsters antifungal pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Company News

Castlefield
Apr 27th, 2026
Engagement update with Merck & co on animal testing and packaging.

Engagement update with Merck & co on animal testing and packaging. By Ffion Spencer * Share * April 27/04/2026, 12:00 AM As part of its ongoing efforts to improve performance across key environmental, social, transparency and governance (E.S.T.) metrics, Castlefield Partners Limited recently engaged with US pharmaceutical company Merck & co., held in the castlefield thoughtful World Equity Fund, to discuss its approach to animal testing, the use of animal-derived ingredients, and packaging practices. At a recent External Advisory Committee meeting, the committee highlighted increasing numbers of animals being used in animal testing across the pharmaceutical sector. Around the same time, Castlefield Partners Limited also received a client query relating to the use of animal derived ingredients in pharmaceutical products. This engagement therefore focused on three material topics for the pharmaceutical industry: animal testing, the use of animal derived ingredients in products, and plastic use. In its initial response, Merck explained that it makes extensive use of non animal research methods, including in vitro techniques, computer modelling and advanced imaging, prior to or instead of animal studies. The company shared that approximately 96% of its research animals are rodents and confirmed that it maintains detailed records on animal use across species, purpose and site, including research carried out by third party organisations on Merck's behalf. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. While this response suggests a baseline level of governance and oversight, Castlefield Partners Limited believe there is scope for further progress. Castlefield Partners Limited has followed up and are awaiting further written responses.Castlefield Partners Limited note that some peers, including French pharmaceutical company Sanofi, which is also held in the World Equity Fund, publish the total number of animals used for scientific research on an annual basis. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. On animal derived ingredients, Merck highlighted the use of specialised tools to identify potential non animal alternatives, indicating consideration of reduction and substitution where scientifically feasible. On plastics, the company shared that it has developed a long term roadmap aimed at reducing the environmental impact of its packaging, suggesting an acknowledgement of plastics as a material environmental issue within its operations. Overall, while Merck provided high level information across all three topics, the most detailed discussion related to animal testing, reflecting its materiality to the sector. Outcome: Its engagement confirmed that Merck has a level of baseline governance on these topics. However, further engagement with the company is required, particularly in relation to transparency and disclosure on the number of animals used in scientific testing. Information is accurate as at 20.04.2026. Opinions constitute the fund manager's judgement as of this date and are subject to change without warning. The officers, employees and agents of CIP may have positions in any securities mentioned herein. This material may not be distributed, published or reproduced in whole or in part. With investment, capital is at risk.

Yahoo Finance
Apr 14th, 2026
Merck keeps Keytruda cancer drug prices high as single dose reaches $163K

Merck's cancer drug Keytruda has become a pricing flashpoint in US healthcare, with a single 400mg dose billed at $162,567 at a California clinic, despite Merck's list price of $24,000. The drug generated $31.7 billion in worldwide sales in 2025, representing nearly half of Merck's revenue. A joint investigation by the International Consortium of Investigative Journalists and USA TODAY found Merck employs multiple tactics to maintain high prices, including building patent walls against generic competition, lobbying against Medicare price negotiations, and maintaining higher dosing despite studies suggesting weight-based dosing would be effective and cheaper. Whilst Merck CEO Robert Davis pledged support for President Trump's drug pricing initiatives in December, he made no commitments regarding Keytruda. Merck attributes US price inflation to pharmacy benefit managers and insurers who add fees and rebates.

Longevity.Technology
Apr 9th, 2026
Merck bets $838M on antibody startup Infinimmune for faster drug discovery

Merck has announced a collaboration with Infinimmune, a California-based biotech founded in 2022, worth up to $838 million to discover new antibody drug candidates. The deal targets multiple undisclosed targets selected by Merck, though upfront payment details were not disclosed. Infinimmune's platform identifies promising antibodies by studying memory B cells from the human immune system. The company claims it can identify antibodies binding to a target within one week and prepare candidates for animal studies in roughly three months. Chief executive Wyatt McDonnell described the approach as building a massive database of immune cell information that can be searched for matching antibodies. The 10-person startup is also developing IFX-101, its lead candidate for moderate-to-severe atopic dermatitis, designed for quarterly or twice-yearly dosing.

Yahoo Finance
Apr 7th, 2026
JPMorgan raises Merck price target to $135 as EU approves KEYTRUDA for ovarian cancer

Merck & Co. (NYSE: MRK) received a price target increase from JPMorgan to $135 from $125 on 6 April, maintaining an Overweight rating ahead of its 30 April earnings report. The firm highlighted Merck's pipeline as the primary focus, citing a favourable risk-return setup with key data readouts expected in 2026 and 2027. On 2 April, Merck announced EU approval for KEYTRUDA combined with paclitaxel for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma. The approval marks the first PD-1 inhibitor-based option for eligible patients with platinum-resistant ovarian cancer in the EU and extends across all 27 member states plus Iceland, Liechtenstein and Norway.

Ophthalmology Times
Apr 7th, 2026
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD.

Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD. MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg). Merck has initiated MALBEC, its phase 2b/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (AMD). MK-8748 is defined by the company as a "novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits VEGF with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula." According to the company, preclinical evidence may suggest that dual pathway modulation helps improve vascular stability in the retina and supports vision preservation in patients with certain vascular retinal diseases.[1] MALBEC is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg). The primary endpoint of the trial is mean change in best-corrected visual acuity (BCVA) from baseline to Year 1 in the study eye of the participants, using standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) vision. Patients will be randomized 1:1:1 to receive 2 dose regimens of MK-8748 or aflibercept 2mg. Patients will initially receive 3 monthly doses of MK-8748 or aflibercept 2mg. These doses will be followed by treatments every 8 weeks until week 48. Following week 48, patients will be treated at intervals determined based on individualized response to treatment, with the last study visit at week 96. David Guyer, MD, founder, CEO and president of, commented on the trial in a press release from the company, saying, "Despite available therapies, many patients with neovascular age-related macular degeneration remain at risk of further vision loss due to continued vascular leakage. With its differentiated dual mechanism directly agonizing Tie2 and inhibiting VEGF, MK-8748 has the potential to offer a novel approach to maintain vascular stability for patients with serious retinal diseases." In addition to MALBEC, the company intends to initiate a second study in wet AMD in 2026. The company noted that the plan to advance into pivotal studies is based on results from the Phase 1/2a RIOJA trial, which was a 2-part study evaluating MK-8748 in patients with either wet AMD, macular edema secondary to branch retinal vein occlusion (BRVO), or diabetic macular edema (DME). In addition to MK-8748, Merck is developing MK-3000 (also known as Restoret, EYE103) for the treatment of DME. MK-3000 is currently being evaluated in the BRUNELLO trial, a randomized, double-masked trial evaluating the efficacy and safety of 2 dose levels of intravitreal MK-3000 versus active control ranibizumab.[2] References: Don't miss out - get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

INACTIVE